{"id":"NCT00910104","sponsor":"Mark Puder","briefTitle":"Cholestasis Reversal: Efficacy of IV Fish Oil","officialTitle":"Cholestasis Reversal: Efficacy of IV Fish Oil","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-08","primaryCompletion":"2019-01-23","completion":"2019-01-23","firstPosted":"2009-05-29","resultsPosted":"2024-09-19","lastUpdate":"2024-09-19"},"enrollment":91,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Parenteral Nutrition Associated Liver Disease","Short Bowel Syndrome","Gastrointestinal Disease"],"interventions":[{"type":"DRUG","name":"OmegavenÂ®","otherNames":["Fish Oil Lipid Emulsion (FOLE)"]}],"arms":[{"label":"Omegaven","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine whether Omegaven is effective in the treatment of parenteral nutrition associated liver disease (PNALD).","primaryOutcome":{"measure":"Reversal of Cholestasis, Defined as a Direct Bilirubin to <= 2.0 mg/dL.","timeFrame":"Duration of treatment","effectByArm":[{"arm":"Omegaven","deltaMin":11.7,"sd":null},{"arm":"Intralipid (Historical Control)","deltaMin":6.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.001"},{"comp":"OG000 vs OG001","p":"0.001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["18310188","16818533","27979360","27510535","26962059","24374535","21775562","19661785","34695449","33038344","32059815"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":42},"commonTop":["Hypertriglyceridemia","INR > 2.0","Essential fatty acid deficiency"]}}